Extrodinary General Shareholders’ Meeting
IRVINE, CA, and HERSTAL, BELGIUM – 14:30 CEST, June 19 2017 – MDxHealth SA (Euronext: MDXH.BR) held today its Extraordinary General Shareholders’ Meeting in Brussels. The shareholders approved all agenda items of the Extraordinary General Shareholders’ Meeting.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
Jean-Marc Roelandt, Chief Financial Officer
+32 (0) 4 364 20 70
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.